Doxorubicin-vincristine therapy for Wilms' tumor: a pilot study
Camitta, B.; Kun, L.; Glicklich, M.; Oechler, H.; Adair, S.; Pinkel, D.
Cancer Treatment Reports 66(10): 1791-1794
1982
ISSN/ISBN: 0361-5960 PMID: 6290049 Document Number: 195109
Doxorubicin plus vincristine chemotherapy was given to 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is greater than 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.